CYBB and COVID-19: Interestingly, hydroxychloroquine (HCQ), the antimalarial drug, used to treat COVID-19, has been recently demonstrated to inhibit Nox2 activity through the ability to alkalize endosomes and therefore impedes antiphospholipd antibody activity (aPL) [35, 140].